Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1061)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2470)
  2. Solid Tumor Oncology Division (1885)
  3. Hematologic Malignancies, Division of (1191)
  4. GSK Faculty (1125)
  5. Department of Pathology and Laboratory Medicine (917)
  6. Epidemiology and Biostatistics (863)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (166)

More People

Years
  1. 2025 (152)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (547)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (618)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Current use of CAR T cells to treat multiple myeloma
    Review

    Firestone, R. S.; Mailankody, S.
    Hematology-American Society of Hematology Education Program (2023)

    Fulltext@MSK | Save
  • Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: Results from a retrospective worldwide registry
    Journal Article

    Hindi, N.; Razak, A.; Rosembaum, E.; Jonczak, E.; Hamacher, R.; Rutkowski, P.; Bhadri, V. A.; Skryd, A.; Brahmi, M.; Alshibany, A.; more...
    ESMO Open (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer
    Meeting Abstract

    Zammarrelli, W.; Ma, W.; Espino, K.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N.; Aghajanian, C.; Green, A.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2
    Meeting Abstract

    Gordhandas, S.; Yen, T. T.; Ingber, S.; Kahn, R.; Kayani, S.; Taffuri, A.; Sokolowski, S.; Martinez, D.; Garcia, P.; Mullangi, S.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma
    Meeting Abstract

    Liu, J.; Colombo, N.; Oza, A.; Frenel, J. S.; Corr, B.; Rubinstein, M.; Nevadunsky, N.; Lheureux, S.; Gaba, L.; Cortijo, L. G.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Oncolytic immunotherapy with recombinant Newcastle disease virus-encoding interleukin-12 in ovarian cancer mouse models
    Meeting Abstract

    Kahn, R.; Green, H.; Pesci, G.; Burman, B.; Praiss, A.; Ozsoy, M.; Brodeur, M.; Bhaloo, S. I.; Abu-Rustum, N.; Chi, D.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Ipilimumab after CD34-selected allogeneic stem cell transplantation (Allo HCT) for patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Ghosh, A.; Nagel, K.; Hosszu, K.; Datta, A.; Thompson, C.; Levia, K.; Kamrowski, A.; McAvoy, D.; Chung, D.; Landau, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save